Traditional smallpox vaccination with reduced risk of inadvertent contact spread by administration of povidone iodine ointment

Vaccine

Volumn 26, Issue 3, 2008, Pages 430-439

  Hammarlund, Erika ^a   Lewis, Matthew W ^a   Hanifin, Jon M ^a   Simpson, Eric L ^a   Carlson, Nichole E ^a   Slifka, Mark K ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Povidone iodine ointment; Smallpox vaccination; Vaccinia

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; POVIDONE IODINE; SMALLPOX VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; FEMALE; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; MALE; PRIORITY JOURNAL; RISK REDUCTION; SMALLPOX; T LYMPHOCYTE; VIRUS INACTIVATION; VIRUS SHEDDING;

ADMINISTRATION, CUTANEOUS; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; POVIDONE-IODINE; RISK FACTORS; SKIN; SMALLPOX; SMALLPOX VACCINE; TREATMENT OUTCOME; VACCINATION; VACCINIA; VACCINIA VIRUS; VIRUS SHEDDING;

EID: 37549039828     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.10.070     Document Type: Article

References (45)

1. Henderson D.A. The looming threat of bioterrorism. Science 283 5406 (1999) 1279-1282
2. Henderson D.A., Inglesby T.V., Bartlett J.G., Ascher M.S., Eitzen E., Jahrling P.B., et al. Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 281 22 (1999) 2127-2137
3. Smith G.L., and McFadden G. Smallpox: anything to declare?. Nat Rev Immunol 2 7 (2002) 521-527
4. Rimoin A.W., Kisalu N., Kebela-Ilunga B., Mukaba T., Wright L.L., Formenty P., et al. Endemic human monkeypox, Democratic Republic of Congo 2001-2004. Emerg Infect Dis 13 6 (2007) 934-937
5. Damon I.K., Roth C.E., and Chowdhary V. Discovery of monkeypox in Sudan. N Engl J Med 355 9 (2006) 962-963
6. Reed K.D., Melski J.W., Graham M.B., Regnery R.L., Sotir M.J., Wegner M.V., et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 350 4 (2004) 342-350
7. Hammarlund E., Lewis M.W., Carter S.V., Amanna I., Hansen S.G., Strelow L.I., et al. Multiple diagnostic techniques identify previously vaccinated individuals with protective immunity against monkeypox. Nat Med 11 9 (2005) 1005-1011
8. Sejvar J.J., Chowdary Y., Schomogyi M., Stevens J., Patel J., Karem K., et al. Human monkeypox infection: a family cluster in the midwestern United States. J Infect Dis 190 10 (2004) 1833-1840
9. Lewis M.W., Graham M.B., Hammarlund E., Hanifin J., and Slifka M.K. Monkeypox without exanthem. N Engl J Med 356 20 (2007) 2112-2114
10. Fenner F., Henderson D.A., Arita I., Jezek Z., and Ladnyi I.D. Smallpox and its eradication. The pathogenesis, immunology, and pathology of smallpox and vaccinia. (1988), World Health Organization, Geneva
11. Kretzschmar M., Wallinga J., Teunis P., Xing S., and Mikolajczyk R. Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med 3 (2006) 8
12. Neff J.M., Lane J.M., Fulginiti V.A., and Henderson D.A. Contact vaccinia-transmission of vaccinia from smallpox vaccination. JAMA 288 15 (2002) 1901-1905
13. Copeman P.W., Wallace H.J., and Vaccinatum E. Br Med J 2 5414 (1964) 906-908
14. Greenberg M. Complications of vaccination against smallpox. Am J Dis Child 76 (1948) 492-502
15. Lane J.M., Ruben F.L., Abrutyn E., and Millar J.D. Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968. JAMA 212 3 (1970) 441-444
16. CDC. Household transmission of vaccinia virus from contact with a military smallpox vaccinee-Illinois and Indiana, 2007. MMWR Morb Mortal Wkly Rep 2007;56(19):478-81.
17. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 9 9 (2003) 1131-1137
18. Fenner F. Mouse-pox; infectious ectromelia of mice: a review. J Immunol 63 4 (1949) 341-373
19. Tanabe I., and Hotta S. Effect of disinfectants on variola virus in cell culture. Appl Environ Microbiol 32 2 (1976) 209-212
20. Ferrier A., Garin D., and Crance J.M. Rapid inactivation of vaccinia virus in suspension and dried on surfaces. J Hosp Infect 57 1 (2004) 73-79
21. Butcher W., and Ulaeto D. Contact inactivation of orthopoxviruses by household disinfectants. J Appl Microbiol 99 2 (2005) 279-284
22. Wallbank A.M., Drulak M., Poffenroth L., Barnes C., Kay C., and Lebtag I. Wescodyne: lack of activity against poliovirus in the presence of organic matter. Health Lab Sci 15 3 (1978) 133-137
23. Weber D.J., Barbee S.L., Sobsey M.D., and Rutala W.A. The effect of blood on the antiviral activity of sodium hypochlorite, a phenolic, and a quaternary ammonium compound. Infect Control Hosp Epidemiol 20 12 (1999) 821-827
24. Hanson P.J., Gor D., Jeffries D.J., and Collins J.V. Chemical inactivation of HIV on surfaces. BMJ 298 6677 (1989) 862-864
25. Maris P. Virucidal efficacy of eight disinfectants against pneumovirus, coronavirus and parvovirus. Ann Rech Vet 21 4 (1990) 275-279
26. Noda M., Matsuda S., and Kobayashi M. Virucidal activity of disinfectants influence of the serum protein upon the virucidal activity of disinfectants. Kansenshogaku Zasshi 74 8 (2000) 664-669
27. Frey S.E., Newman F.K., Yan L., and Belshe R.B. Response to smallpox vaccine in persons immunized in the distant past. JAMA 289 24 (2003) 3295-3299
28. Graham B.S., Belshe R.B., Clements M.L., Dolin R., Corey L., Wright P.F., et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial The AIDS Vaccine Clinical Trials Network. J Infect Dis 166 2 (1992) 244-252
29. Waibel K.H., Ager E.P., Topolski R.L., and Walsh D.S. Randomized trial comparing vaccinia on the external surfaces of 3 conventional bandages applied to smallpox vaccination sites in primary vaccinees. Clin Infect Dis 39 7 (2004) 1004-1007
30. Hepburn M.J., Dooley D.P., Murray C.K., Hospenthal D.R., Hill B.L., Nauschuetz W.N., et al. Frequency of vaccinia virus isolation on semipermeable versus nonocclusive dressings covering smallpox vaccination sites in hospital personnel. Am J Infect Control 32 3 (2004) 126-130
31. Talbot T.R., Peters J., Yan L., Wright P.F., and Edwards K.M. Optimal bandaging of smallpox vaccination sites to decrease the potential for secondary vaccinia transmission without impairing lesion healing. Infect Control Hosp Epidemiol 27 11 (2006) 1184-1192
32. Amara R.R., Nigam P., Sharma S., Liu J., and Bostik V. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 78 8 (2004) 3811-3816
33. Couzi G., and Kircher J.P. Immunotherapie de la Variole. Bulletin de l'Institut d'hygiene du Maroc 1 (1941) 59-68
34. Kempe C.H. Studies on smallpox and complications of smallpox vaccination. Pediatrics 25 (1960) 176-189
35. Kempe C.H., Bowles C., Meiklejohn G., Berge T.O.St., Vincent L., Babu B.V.S., et al. The use of vaccinia hyperimmune gammaglobulin in the prophylaxis of smallpox. Bull WHO 25 (1961) 41-48
36. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., et al. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 11 7 (2005) 740-747
37. Mack T.M., Noble Jr. J., and Thomas D.B. A prospective study of serum antibody and protection against smallpox. Am J Trop Med Hyg 21 2 (1972) 214-218
38. Fillmore G.L., Ward T.P., Bower K.S., Dudenhoefer E.J., Grabenstein J.D., Berry G.K., et al. Ocular complications in the Department of Defense Smallpox Vaccination Program. Ophthalmology 111 11 (2004) 2086-2093
39. Secondary and tertiary transfer of vaccinia virus among U.S. military personnel-United States and worldwide, 2002-2004. MMWR Morb Mortal Wkly Rep 2004;53(5):103-5.
40. Garde V., Harper D., and Fairchok M.P. Tertiary contact vaccinia in a breastfeeding infant. JAMA 291 6 (2004) 725-727
41. Jonczy E.A., Daly J., and Kotwal G.J. A novel approach using an attenuated recombinant vaccinia virus to test the antipoxviral effects of handsoaps. Antiviral Res 45 2 (2000) 149-153
42. Nalca A., Rimoin A.W., Bavari S., and Whitehouse C.A. Reemergence of monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis 41 12 (2005) 1765-1771
43. Levine RS, Peterson AT, Yorita KL, Carroll D, Damon IK, Reynolds MG. Ecological niche and geographic distribution of human monkeypox in Africa. PLoS ONE 2007;2:e176.
44. Jenner E. An inquiry into the causes and effects of the variolae vaccinae (1798), Sampson Low, London
45. Jenner E. Further observations on the variolae vaccinae. (1799), Sampson Low, London